Pulse-Dose Steroids Not Superior to Lower-Dose Regimen in AE-IPF

This multicenter, randomized, open-label trial (SAFER) conducted at eight South Korean university hospitals compared pulse-dose methylprednisolone (10 mg/kg for 3 days) with a nonpulse regimen (1 mg/kg for 7 days) in 100 adults with acute exacerbation of idiopathic pulmonary fibrosis. The trial reported no significant difference in 28-day mortality (10.0% vs 14.6%) or 90-day mortality (24.5% vs 29.8%) between the pulse and nonpulse groups, and secondary outcomes including ICU admission, mechanical ventilation, and ECMO use were also not demonstrably different. The authors concluded that pulse-dose methylprednisolone did not demonstrate improved survival compared with the nonpulse regimen.

Most relevant for: Adults with acute exacerbation of idiopathic pulmonary fibrosis being considered for corticosteroid therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.